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Abstract. Daikenchuto (TU‑100) is a traditional Japanese 
medicine that is widely used to treat intestinal symptoms. The 
mechanisms underlying it effects on the circulating levels of 
adrenomedullin (ADM) are of interest. In addition, the effect 
of TU‑100 in the treatment of Crohn's disease (CD) in humans 
remains to be elucidated. The primary objective of the present 
study was to evaluate the effect of TU‑100 on the circulating 
ADM levels in patients with active CD. An additional objec‑
tive was to assess the effect of the drug on the disease activity 
and its potential side effects. In an open‑label study, 10 patients 
with active CD received 15 g TU‑100 per day for 8 consecutive 
weeks, and baseline anti‑inflammatory therapy was continued. 
The pre‑ and post‑treatment blood plasma levels of total 
ADM (t‑ADM) and mature‑ADM (m‑ADM) were determined 
using enzyme‑linked immunosorbent assays. The response 
of patients to the treatment was evaluated clinically using 
the International Organization for the Study of Inflammatory 
Bowel Diseases (IOIBD) score. The plasma levels of t‑ADM 
(16.4±1.1 vs. 20.2±1.7 fmol/ml, P=0.0218) and m‑ADM 
(1.7±0.1 vs. 2.2±0.1 fmol/ml, P=0.0284) increased following 
8 weeks of TU‑100 treatment, compared with control. The 
IOIBD score of patients also improved, with a significant 
decrease in the score from 3.9±0.5 at 0 weeks to 2.4±0.4 at 
8 weeks (P=0.0284). Out of the 10 components of the IOIBD 
scoring system, the scores for abdominal pain and tenderness, 
decreased significantly (P=0.014 and P=0.046). Therefore, 
TU‑100 was safe and well‑tolerated by the patients that partici‑
pated in the current study. The present study determined that 
the pharmacologic action of TU‑100 is associated with changes 
in the circulating ADM levels and that treatment with TU‑100 
may aid in the management of CD. These promising findings 
warrant further investigation in larger, multicenter studies.
Introduction
Crohn's disease (CD) is a chronic inflammatory disorder of 
the gastrointestinal tract. The precise cause remains unknown; 
however, genetic, immunological, infective and environmental 
factors have been proposed to contribute to its pathogen‑
esis (1,2).
Advances in the understanding of the pathogenesis of CD 
over the last decade have enabled the development of agents 
directed at rational therapeutic targets. Selective blocking of 
inflammatory cytokines through the introduction of novel 
biologicals, including anti‑tumor necrosis factor‑α agents, 
has yielded considerable clinical benefit (3). This approach 
validated the targeting of inflammatory cytokines as a 
strategy for treating ongoing disease; however, the long‑term 
safety and efficacy of such therapeutic agents remains uncer‑
tain. Additionally, certain patients may not respond to this 
treatment, exhibit intolerance, or both. Thus, result in the 
requirement of an alternative therapeutic approach. The other 
treatments currently available include total parenteral nutri‑
tion and elemental diets, restriction of oral food intake and 
in severe cases, hospitalization. Therefore, a safer and more 
effective treatment method for CD is desirable.
Daikenchuto (TU‑100) is a traditional Japanese herbal 
medicine (Kampo), which consists of a mixture of powdered 
extracts of dried Japanese pepper, processed ginger and 
ginseng radix, and maltose powder (4). TU‑100 is a frequently 
prescribed Kampo medicine in Japan, particularly for the 
treatment of postoperative paralytic and adhesive ileus and 
ischemic intestinal disorders (5‑8). Previous studies have 
demonstrated the effects of TU‑100 on intestinal motility, 
adhesion, vasodilatation, inflammation and bacterial transloca‑
tion (9‑11). A previous study reported that the beneficial effect 
of TU‑100 is primarily mediated by the increased release of 
adrenomedullin (ADM) from intestinal epithelial cells (12).
ADM, is a 52‑amino‑acid peptide, which was originally 
identified in human pheochromocytoma tissue. Subsequent 
studies have demonstrated that the ADM protein and mRNA are 
widely distributed in various tissues and organs (13‑15). ADM 
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promotes vasodilation, tissue repair and anti‑inflammatory 
actions in the intestine. Exogenous administration of ADM has 
been demonstrated to exhibit therapeutic potential in various 
models of inflammatory disease, including colitis (16‑18) and 
arthritis (19). In addition, it has been reported that TU‑100 
exerted beneficial effects in a mouse model of colitis through 
the induction of ADM release (20,21).
On the basis of these previous studies, double‑blind placebo 
controlled randomized clinical trials using TU‑100 in patients 
with CD, postoperative paralytic ileus, functional constipation 
and irritable bowel syndrome have been conducted in Japan 
(funded by the Japanese Foundation For Multidisciplinary 
Treatment of Cancer: Identifier nos. JFMC39‑0902, 
JFMC40‑1001 and JFMC42‑1002) and the United States 
(identifier nos. NCT00871325, NCT01139216, NCT01388933, 
and NCT01348152). However, to the best of our knowledge, 
the effects of TU‑100 on the blood plasma levels of ADM in 
patients with CD have not been described previously.
The primary aim of the current study was to evaluate the 
efficacy of TU‑100 treatment on the circulating ADM levels 
in patients with active CD. Additional objectives included the 
assessment of the effect of the drug on the disease activity and 
its safety.
Materials and methods
Ethical approval. This project was performed in accordance 
with the principles laid out in the Declaration of Helsinki and 
with the approval of the Medical Ethics Committee of Kurume 
University Hospital (Kurume, Japan). Written informed 
consent was obtained from the participants.
TU‑100 preparation. TU‑100 was prepared as a dried powdered 
extract of Panacis Ginseng Radix (3.0 g), Zanthoxyli Fructus 
(2.0 g) and Zingiberis Siccatum Rhizoma (5.0 g), purchased 
from Tsumura & Co., Ltd. (Tokyo, Japan).
Detection of ADM blood plasma levels. ADM occurs in two 
molecular forms, the active and mature ADM (m‑ADM) form 
and the inactive and glycine‑extended ADM (gly‑ADM)
form (22). Total ADM (t‑ADM) is the sum of the levels of 
m‑ADM and gly‑ADM. The present study determined the 
plasma levels of m‑ADM and t‑ADM by enzyme‑linked immu‑
nosorbent assays (ELISA; Shionogi & Co., Ltd., Tokyo, Japan). 
These assay systems use two monoclonal antibodies against 
human ADM, one that recognizes the ring structure of human 
ADM in each kit and another that recognizes the C‑terminal 
sequence in the m‑ADM kit or ADM‑ (25‑36) in the t‑AM kit. 
The assay determined human m‑ADM or t‑ADM by placing 
it between the two antibodies without plasma extraction. The 
detection limit was 2 fmol/ml for t‑ADM and 1 fmol/ml for 
m‑ADM. The plasma levels of calcitonin gene‑related peptide 
(CGRP) were also determined by ELISA; the detection limit 
of this assay was 7.8 pg/ml (Bertin Pharma, Montigny le 
Bretonneux, France).
Patient selection and study design. An open‑label, prelimi‑
nary trial was conducted at Kurume University School of 
Medicine between September 2007 and June 2008. A total 
of 10 patients with active CD (3 men, 7 women; mean age, 
37.3 years; mean duration of CD, 11.7 years) participated in 
this study (Table I). The diagnosis of CD was based on char‑
acteristic clinical, endoscopic, radiological and histological 
features. The patients had been unresponsive or intolerant to 
the standard treatment methods for CD for at least 4 weeks. 
All baseline anti‑inflammatory therapies were continued 
throughout the current study (Table I). No dietary alterations 
were made after the patients entered the study.
Patients received 15 g TU‑100 (5 g three times a day 
administered orally) per day for 8 consecutive weeks. Plasma 
levels of m‑ADM, t‑ADM and CGRP were determined before 
and after the 8‑week administration.
The response to the treatment was evaluated biweekly 
using the routine laboratory variables, including serum hemo‑
globin and C‑reactive protein (CRP) and the International 
Organization for the Study of Inflammatory Bowel Disease 
(IOIBD) score (23). The IOIBD score is based on 10 compo‑
nents, specifically the presence/absence of: i) Abdominal pain, 
ii) bowel evacuation 6 times or more per day, iii) anal lesion, 
iv) fistula, v) complication, vi) abdominal tumor, vii) body 
weight decrease, viii) fever of 38˚C or higher, ix) abdominal 
tenderness and x) hemoglobin level of 10 g/dl or lower. 
Presence of each of these components is assigned 1 point, and 
the total number of points is expressed as the IOIBD score of 
the patients.
Table I. Characteristics of 10 patients with active CD who 
completed 8 weeks of treatment with TU‑100.
Total number of patients 10
Mean age ± SE (years) 37.3±15.5
Number of males 3
Mean duration of disease since  
diagnosis ± SE (years) 11.7±13.2
Mean baseline IOIBD ± SE 3.9±0.55
Mean baseline CRP ± SE (mg/dl) 1.2±0.3
Location of disease, n
  Ilial 2
  Colonic 1
  Ileocolonic 7
Disease behavior, n
  Inflammatory 1
  Stricturing 6
  Penetrating 3
Previous intestinal resection, n 6
Concomitant medication, n (%)
  Mesalamine 10 (100)
  Corticosteroids 4 (40)
  Antibiotics 0 (0)
  Azathioprine 1 (10)
  Anti ‑tumor necrosis factor 2 (20)
  Nutritional therapy 7 (70)
CD, Crohn's disease; IOIBD, International Organization for the 
Study of Inflammatory Bowel Diseases; CRP, C‑reactive protein; SD, 
standard deviation.
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Statistical analysis. Results are expressed as the mean ± stan‑
dard error. All the statistical analyses were performed using 
SPSS version 12.0.2 J (SPSS Inc., Chicago, IL, USA). Data 
were compared using Wilcoxon signed‑rank tests or paired 
Student's t tests. Spearman's rank correlation test was used 
where appropriate. P<0.05 was considered to indicate a statis‑
tically significant difference.
Results
Effect of TU‑100 on the circulating ADM levels. The t‑ADM 
and m‑ADM levels in blood plasma of patients at the begin‑
ning and the end of treatment with TU‑100 are presented in 
Fig. 1. Detectable levels of ADM were identified in all of the 
plasma samples. Following 8 weeks of treatment with TU‑100, 
the patients had significantly elevated levels of plasma t‑ADM 
(20.2±1.7 fmol/ml) compared with levels prior to treatment 
(16.4±1.1 fmol/ml; P=0.0218) and plasma m‑ADM (2.2±0.1 vs. 
1.7±0.1 fmol/ml; P=0.0284). Simultaneous determinations 
revealed the absence of detectable CGRP in the plasma in the 
majority of subjects. 
Effect of TU‑100 on the disease activity of CD. The changes 
in the activity of the disease during TU‑100 treatment are 
presented in Fig. 2. The IOIBD score significantly improved 
over time, with a decrease in the score from 3.9±0.5 to 2.4±0.4 
(P=0.0284). A favorable trend was observed in the serum CRP 
concentration; however, no significant difference was identi‑
fied. The effect of TU‑100 treatment on the components of the 
IOIBD scoring system was also examined (Fig. 3). Out of the 
10 components, the scores for abdominal pain and tenderness 
were significantly decreased after 8 weeks when compared 
with the scores at the start of the study (P=0.014 and P=0.046, 
respectively). No significant differences were identified for the 
remaining components. 
Correlation between the circulating levels of ADM and the 
disease activity. As presented in Fig. 4, no significant associa‑
tion was observed between the plasma concentrations of ADM 
and the IOIBD scores or serum CRP levels.
Side effects. TU‑100 was well tolerated in all 10 patients 
enrolled in the present study. The patients felt well and did 
not experience any side effects. No febrile or allergic reactions 
were observed. No changes were encountered in the routine 
blood biochemical parameters, including liver and renal func‑
tion tests, during/after TU‑100 treatment. Additionally, no 
adverse events related to TU‑100 were observed.
Discussion
To the best of our knowledge, the present study was the first 
to evaluate the efficacy, circulating levels of ADM, disease 
activity and safety of TU‑100 in patients with CD.
Due to the heterogeneous nature of TU‑100, the under‑
lying mechanism of its therapeutic effect has not been fully 
elucidated. However, observations in animal models indicate 
that the effect of TU‑100 may be attributed to the induction 
of ADM release. TU‑100 also improves colonic injury by 
enhancing endogenous ADM release (20). Additionally, 
the beneficial effect of TU‑100 was reduced by an ADM 
inhibitor (11). Systemically administered ADM had a similar 
beneficial effect on colonic injury (16‑19).
Therefore, there was considerable interest in determining 
whether TU‑100 promoted ADM release in patients with CD. 
The present study determined that TU‑100 treatment induced 
the release of the active form of ADM, which possibly resulted 
in a significant improvement of the disease activity. These 
findings suggest that the efficacy of TU‑100 against CD may 
be contributed to the induction of ADM release. To the best 
of our knowledge, the present study was the first to determine 
the circulating levels of ADM in blood plasma during TU‑100 
treatment in humans. At present, the current findings on the 
clinical response of patients with CD to TU‑100 are prelimi‑
nary. However, as TU‑100 has been observed to promote ADM 
release in human subjects is encouraging and further clinical 
investigations should be performed.
The mechanisms underlying the effect of TU‑100 on 
the release of ADM remain to be fully elucidated. TU‑100 
Figure 1. Plasma concentrations of t‑ADM, m‑ADM and gly‑ADM of the 
10 patients with Crohn's disease before and after treatment with TU‑100 for 
8 weeks. The plasma concentrations of t‑ADM and m‑ADM were determined 
using enzyme‑linked immunosorbent assays, whereas those of gly‑ADM 
were calculated by the subtraction of the plasma m‑ADM concentrations 
from the plasma t‑ADM concentrations. t‑ADM, total ADM; m‑ADM, 
mature ADM; gly‑ADM, glycine‑extended ADM.
Figure 2. IOIBD scores and serum CRP levels of the 10 patients with 
Crohn's disease before and after treatment with TU‑100 for 8 weeks. 
IOIBD, International Organization for the Study of Inflammatory Bowel 
Disease; CRP, C‑reactive protein.
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components, including 6‑shogaol and hydroxy‑α‑sanshool, 
contain an activator of the Transient Receptor Potential 
(TRP)‑channels (4). Kono et al (24) demonstrated that TU‑100 
and its component 6‑shogaol increase the intestinal blood flow 
via enhancement of ADM release mediated by the stimulation 
of TRP ankyrin 1 in intestinal epithelial cells (24). It possible 
that a component of TU‑100, such as 6‑shogaol, is respon‑
sible for ADM release through TRP channel stimulation. 
Determination of the signaling pathways involved in the TRP 
channel‑ADM axis is an important area for further investiga‑
tion.
No direct correlation was observed between the circulating 
levels of ADM and the IOIBD scores during TU‑100 treat‑
ment. Therefore, an additional unrecognized peptide may be 
involved in the response to TU‑100 treatment, in addition to 
ADM. Further investigation is required to elucidate the precise 
mechanisms underlying the actions of TU‑100 action in human 
patients with CD.
The primary advantage of TU‑100 is that it appears to lack 
any side effects or toxicity (4). In particular, TU‑100 led to no 
allergic reactions or any significant changes in blood biochem‑
ical parameters, including liver and renal function tests, during 
the study period. Standard therapy for CD consists of drugs 
that primarily act on the intestinal immune‑component cells, 
including lymphocytes and macrophages to reduce the release 
of various inflammatory mediators (3). However, the preven‑
tive action of TU‑100 differs from these anti‑inflammatory 
approaches. Combined therapy of TU‑100 and standard thera‑
peutic agents is of interest and warrants evaluation.
The findings of the current study suggest that treating CD 
using ADM may be a novel approach to treat CD (16‑19). In 
addition, ADM, particularly its active form, are rapidly cleared 
from the blood, which decreases the systemic effects (25). 
By contrast, TU‑100 appears to affect the endogenous ADM 
system not systemically, but locally and in a sustained manner. 
Such sustained and localized increase of ADM induced by 
TU‑100 may be advantageous, as it may lead to the biological 
effect of ADM being primarily confined to the disease 
sites (12).
A potential limitation of the current study is that it included 
a small number of patients. The patients were monitored for 
Figure 3. Score for each item of the IOIBD score in the 10 patients with Crohn's disease before and after treatment with TU‑100 for 8 weeks. IOIBD, International 
Organization for the Study of Inflammatory Bowel Disease; Hb, hemoglobin.
Figure 4. Correlation between the plasma concentrations of t‑ADM, m‑ADM 
and gly‑ADM, and the IOIBD score or serum CRP. IOIBD, International 
Organization for the Study of Inf lammatory Bowel Disease; CRP, 
C‑reactive protein; t‑ADM, total ADM; m‑ADM, mature ADM; gly‑ADM, 
glycine‑extended ADM. 
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8 weeks subsequent to the administration of the drug; however, 
a trial with a greater number of patients and longer‑term 
follow‑up period is required.
In conclusion, the present study provides novel evidence 
to suggest that TU‑100 may be an effective treatment for 
CD, and exerts this effect at least in part through inducing 
the release of ADM. Additionally, no significant side effects 
or toxicity were observed during this trial. Based on these 
encouraging preliminary results, a larger, multicenter random‑
ized controlled clinical trial of this therapeutic agent should be 
conducted for patients with CD.
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